Treatment of Advanced Non-small Cell Lung Cancer with Feiai Heji Combined with Chemotherapy
|更新时间:2024-01-04
|
Treatment of Advanced Non-small Cell Lung Cancer with Feiai Heji Combined with Chemotherapy
Chinese Journal of Experimental Traditional Medical FormulaeVol. 17, Issue 17, Pages: 249-253(2011)
作者机构:
作者简介:
基金信息:
DOI:
CLC:
Published:2011
稿件说明:
移动端阅览
HU Zuo-wei, SUN Yi-na, HUANG Jian-hua, et al. Treatment of Advanced Non-small Cell Lung Cancer with Feiai Heji Combined with Chemotherapy[J]. Chinese journal of experimental traditional medical formulae, 2011, 17(17): 249-253.
DOI:
HU Zuo-wei, SUN Yi-na, HUANG Jian-hua, et al. Treatment of Advanced Non-small Cell Lung Cancer with Feiai Heji Combined with Chemotherapy[J]. Chinese journal of experimental traditional medical formulae, 2011, 17(17): 249-253.DOI:
Treatment of Advanced Non-small Cell Lung Cancer with Feiai Heji Combined with Chemotherapy
CA153值比较有非常显著性差异( P <0.01)。 结论: 肺癌合剂配合化疗可作为中晚期非小细胞肺癌的一种有效、低毒的治疗方案。
Abstract
Objective: to observe the effect of Feiai Heji(FAHJ) in treating patients with advanced non-small-cell lung cancer(NSCLC). Method: Sixty patients with confirmed diagnosis of advanced NSCLC were selected and randomly divided into two groups:Thirty patients in the control group with chemotherapy alone(NP or GP regimen)
Thirty patients in the treated group were administered with FAHJ and chemotherapy(the regimen was as same as the control group).After 2 cycles
two groups were observed with short-term effect
the main symptom improvement
quality of life
weight changes
adverse reactions
changes in tumor markers and other projects. Result: The improvement of clinical symptoms in the treated group were superior to those in the control group.As well as improved the QOL
decreased marrow suppression
nausea
vomit and other adverse reactions and levels of tumor marks(CEA
CA153).But there was no significant difference in the effective rates and the disease control rates between two groups. Conclusion: FAHJ combined with chemotherapy can be used as an effective
low toxicity approach to treat the advanced non-small cell lung cancer.